CD274 and neoplasm: Anti-PD-L1 mAbs used in immunohistochemistry staining (IHC) to classify TPS were different in various studies; IMpower 131 and 132 had a different way of classifying PD-L1 TPS (PD-L1 moderate population was defined as >1% and <50% tumor cell or >1% and <10% immune cell PD-L1 staining, and PD-L1 high population was defined as >50% tumor cell or >10% immune cell PD-L1 staining); only the PD-L1 TPS <1% population in CheckMate 227 received anti-PD-1 mAb + chemotherapy combination (see Table 1).